Thursday, 2nd November Clinical Oncology Society of Australia Annual Scientific Meeting 2023

A multi-disciplinary panel of three leading Medical Oncologists, a Neurosurgeon, Radiation Oncologist and a Nurse Practitioner will discuss the challenges and various treatment strategies for the management of HER2+ mBC patients with CNS disease. They will explore real-world case studies from Australia and share their expert opinions and latest clinical data on supporting treatment decisions made.

Speakers:

• Dr Michelle White, Medical Oncologist, Monash Health

• Dr Sally Baron-Hay, Medical Oncologist, GenesisCare

• A/Prof Augusto Gonzalvo, Neurosurgeon, Austin Health

• Dr Mario Guerrieri, Radiation Oncologist, GenesisCare

• Marisa Stevens, Oncology Nurse Practitioner, St Vincent’s Hospital Melbourne

This breakfast session is designed to engage the audience in a facilitated discussion about the value of extending representation in multidisciplinary meetings to improve care for older patients with cancer. Case examples from breast and non-breast cancer patients will provide opinions from surgical, radiation oncology and medical oncology perspectives. Additional opinions will then be contributed from other perspectives to demonstrate the value of extending this discussion to include geriatrician, nursing/allied health/pharmacy perspectives. A consumer opinion will also be sought to contribute to the discussion.

Panellists:

• Etienne Brain, MedicalOncologist
• Polly Dufton, Cancer Nurse
• Kimberley-Ann Kerr, Cancer Pharmacist
• Wee-Kheng Soo, Geriatrician andMedicalOncologist
• Shalini Vinod, Radiation Oncologist
• Sophie Nightingale, Surgeon
• Winsome Clark, Consumer

Topics to be covered in this breakfast session include:

• Review the KEYTRUDA study data that provides evidence for use of KEYTRUDA in early stage and advanced TNBC

• Understand the KEYTRUDA regimens used in both the early stage and advanced TNBC settings

• Discuss appropriate identification of patients for KEYTRUDA in TNBC

• Discuss best practice AE management for patients prescribe KEYTRUDA in TNBC

Chair: TBC

Speakers:

• Dr Dhanusha Sabanathan - Consultant Medical Oncologist in the Breast service at the Lakeside Specialist Breast Clinic and Nepean Cancer Care Centre

• Mrs Jenny Gilchrist - Clinical Nurse Consultant in breast oncology at Macquarie University Hospital

• New drugs and approaches that have brought about progress - Shom Goel
• Looking for genomic alterations in breast cancer: should these be part of routine care? - Stephen Luen
• Dedicated metastatic breast care nurses- providing expert clinical and supportive care to those with metastatic breast cancer - Kerry Patford
• Oligmetastatic Breast Cancer: Current Status and Future Directions - Steven David

10:15 AM Panel discussion 

• VAD and cancer care - David Speakman
• How useful is advance care planning for informing consent and goals of care in Oncology? - Barbara Hayes
• Opioid Use in Palliative Care: Are we Closer to Personalised Treatment Using Pharmacogenomics? - Aaron K Wong

12:00 PM Panel discussion

• Implant reconstruction - advances and controversies in implant-based reconstruction - Natalie Ngan
• Breast implant safety and the ABDR - Gillian Farrell
• Breast surgery and reconstruction in transgender people - Cheng Hean Lo
• Breast Reconstruction: a patient's perspective - Victoria Gurvich

12:10PM Panel discussion

• Consumer perspective - Challenging assumptions and norms  - Naveena Nekkalapudi
• Using sex positivity as a framework - Eliza Bailey
• Let’s talk about sex, baby: communicating about the sexual side effects of anti-cancer therapies - Safeera Y Hussainy
• Sex life Matters: Informed consent in Cancer treatment - Wendy Vanselow

12:05 PM Panel discussion

• Combined germline and somatic sequencing in breast cancer confirms the pathogenicity of the underlying germline mutation and identifies therapeutically vulnerable tumours.   - Dilanka L De Silva
• Differentiation of Niraparib and Olaparib Brain Penetration in a Mouse Brain Metastatic Tumor Model - Ashish Banerjee
• Employing clinical whole-genome sequencing in the diagnostic work-up of cancer of unknown primary - Richard J Rebello
• MRI-based Radiomics Model for Preoperative Prediction of Lateral Pelvic Lymph Node Metastasis in Locally Advanced Rectal Cancer - Wei Zhao
• Tumor cell-released autophagosomes (TRAPs) promote breast cancer lung metastasis by modulating neutrophil extracellular traps formation - Xiaohe Zhou

• The impact of cause of mismatch repair deficiency and other molecular markers on clinical outcomes with the use of durvalumab in advanced endometrial cancer in the phase 2 PHAEDRA trial (ANZGOG1601). - Yoland C Antill
• An ecological assessment of health system performance, universal health coverage, and socio-cultural factors associated with progress towards cervical cancer elimination targets - Amelia Hyatt
• Exercise delivery is feasible, but recruitment is not for women following treatment for gynaecological: Preliminary findings from the Enhancing treatment outcomes after gynaecological cancer (ACUMEN) study - Grace L Rose
• Empowering People With A Cervix To Own Their Cervical Screening - Scott C Walsberger
• The impact of real-time Patient Reported Outcome Measures (PROMs) on Emergency Department presentations in people with gynaecological cancer - Kate Webber
• Impact of the COVID-19 pandemic on epithelial ovarian cancer diagnosis, management patterns and survival in Victoria: insights from the National Gynae-Oncology Registry - Aleesha Whitely

COSA Nutrition Group Meeting                                            Meeting Room 106

COSA Psycho-Oncology Awards
Tom Reeve Award & Oration, 2023 recipient Dr David Speakman OAM

• Advancing Cancer Control: Strategies for Implementing the Australian Cancer Plan - Dorothy Keefe

Panellists:

Tanya Buchanan - CEO, Cancer Council Australia

Tom Calma AO - National Coordinator, Tackling Indigenous Smoking

Shelley Dolan - CEO, The Royal Melbourne Hospital

Lillian Leigh - Consumer

Paul Villanti - Executive Director, Movember

• Universal germline testing for women with newly diagnosed breast cancer in a multidisciplinary setting – impact and benefit - Geoffrey J Lindeman
• BRCA-P: can denosumab prevent breast cancer in BRCA1 mutation carriers?  - Christine Muttiah
• The role of germline and genomic testing in the management of gynae cancers - Michelle Wilson
• Ensuring ethical and flexible consent in cancer genomic research and clinical practice - Jolyn Hersch

Etienne Brain - Medical oncologist
Caroline Baker - Surgeon
Michael Chao - Radiation oncologist
Lesley Stafford - Clinical psychologist
Marissa Stevens - Nurse practitioner
Kate Stewart - Pathologist
Michelle White - Medical oncologist

• Estimating the number of cancers attributable to low physical activity in Australia - Brigid Lynch
• Using data to drive impact in cancer prevention - Darren Brenner
• Global Supportive Care Initiatives: Improving Cancer Outcomes Through Diet and Exercise - Anna Boltong
• Supporting health behaviour change at scale: what can we achieve with digital behaviour change interventions? - Camille E Short

5:20 PM Panel discussion

• Prevalence of bowel and pelvic floor dysfunction after colorectal cancer surgery and primary cancer treatment - Kin Yin Chan
• Developing a Lung Cancer Rehabilitation core outcome set: An International Delphi Study (UNITE).   - Lara Edbrooke
• Comparing the utility of PLCOm2012 and the USPSTF2021 criteria in selecting high-risk individuals for lung cancer screening in the NSW cohort of the International lung Screening Trial (ILST) - Xinxin Hu
• NAPOLI-3: A randomized, open-label phase 3 study of NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) - Zev A Wainberg

• Exercise Conversations: A Mixed Methods Study Explaining What People With Cancer Need From Their Cancer Care Team To Facilitate Adherence With Exercise Guidelines - Prue Cormie
• Out-of-pocket healthcare costs for people with and without cancer in NSW, Australia - David E Goldsbury
• Costs of palliative care for cancer patients in the public acute healthcare setting: results from a Queensland population data linkage study (COS-Q) - Katharina MD Merollini
• Equity across the cancer care continuum for culturally and linguistically diverse migrant populations living in Queensland, Australia: An exploratory sequential mixed methods study - Brighid BS Scanlon
• Establishing a world-first evidence- and consensus-based clinical pathway for fear of cancer recurrence: optimal on paper, but is it feasible in practice? - Ben Smith
• Cost-effectiveness of germline BRCA testing in metastatic prostate cancer followed by cascade testing of first-degree relatives of mutation carriers. - Srinivas Teppala

Venue: Showtime Events Centre